[{"orgOrder":0,"company":"Kancera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAND567","moa":"Fractalkine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kancera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kancera \/ Inapplicable"},{"orgOrder":0,"company":"Kancera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAND567","moa":"Fractalkine receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kancera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kancera \/ Inapplicable"},{"orgOrder":0,"company":"Kancera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KAND567","moa":"Fractalkine receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kancera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kancera \/ Inapplicable"},{"orgOrder":0,"company":"Kancera","sponsor":"NSGO-CTU","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAND567","moa":"Fractalkine receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kancera \/ NSGO-CTU","highestDevelopmentStatusID":"7","companyTruncated":"Kancera \/ NSGO-CTU"},{"orgOrder":0,"company":"Kancera","sponsor":"LINK Medical Research | Q&Q Labs | CRST Oy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KAND145","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kancera \/ LINK Medical Research | Q&Q Labs | CRST Oy","highestDevelopmentStatusID":"6","companyTruncated":"Kancera \/ LINK Medical Research | Q&Q Labs | CRST Oy"}]